Fannie Mae, Freddie Mac shares tumble after conservatorship comments
COPENHAGEN - Bavarian Nordic A/S (OMX:CSE:BAVA) shares fell 10% after the Danish vaccine maker reported preliminary 2024 results and provided 2025 guidance that failed to impress investors. The company also faced a rating downgrade from Nordea.
Bavarian Nordic announced preliminary 2024 revenue of DKK 5,716 million, driven by strong 22% YoY growth in its Travel Health business to DKK 2,287 million. The Public Preparedness segment generated revenue of DKK 3,206 million, boosted by additional mpox vaccine orders during the outbreak.
The company reported preliminary 2024 EBITDA of DKK 1,603 million, representing a 28% margin, in line with its previous guidance of DKK 1,450-1,700 million and 27-29% margin.
CEO Paul Chaplin commented, "We delivered strong results in 2024 after an extraordinary performance in our Travel Health business, demonstrating a 22% growth year-over-year, combined with additional mpox vaccine orders, as we made significant strides in strengthening the public health response in Africa and other regions during the current outbreak."
While Bavarian Nordic highlighted its plans to launch a chikungunya vaccine for travelers over 12 years in Europe and the US later this year, investors appeared unimpressed with the company’s outlook. The sharp 10% drop in share price suggests market participants were expecting more robust guidance for 2025.
Adding to the negative sentiment, Nordea downgraded Bavarian Nordic’s stock rating from "buy" to "hold," likely contributing to the sell-off.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.